The artificial intelligence (AI) boom is shifting from experimental software to massive infrastructure builds. Choosing between hardware pioneer Cerebras Systems (CBRS +1.00%) and data specialist Innodata (INOD +4.19%) depends on your appetite for risk.
Cerebras Systems manufactures giant chips designed to process AI workloads faster than traditional hardware. Meanwhile, Innodata focuses on the fuel for those chips, providing the high-quality data engineering required to train large language models. Both companies play critical roles in the expanding AI ecosystem, but their financial profiles and market positions differ significantly.
CBRS & INOD: Performance Comparison
Key Financial Metrics
CBRS – Cerebras Systems
$98.80
+1.00% (+$0.98)
INOD – Innodata
$43.66
+4.19% (+$1.76)
Market Cap
$23B
52wk Range
$93.89 – $386.34
Gross Margin
39.00%
P/E Ratio
-43.32
EPS (TTM)
-$2.26
Market Cap
$1.4B
52wk Range
$34.23 – $125.14
Gross Margin
42.31%
P/E Ratio
31.77
EPS (TTM)
$1.32
CBRS – Cerebras Systems
$98.80
+1.00% (+$0.98)
Market Cap
$23B
52wk Range
$93.89 – $386.34
Gross Margin
39.00%
P/E Ratio
-43.32
EPS (TTM)
-$2.26
INOD – Innodata
$43.66
+4.19% (+$1.76)
Market Cap
$1.4B
52wk Range
$34.23 – $125.14
Gross Margin
42.31%
P/E Ratio
31.77
EPS (TTM)
$1.32
The case for Cerebras Systems
Cerebras Systems operates in the competitive semiconductor landscape, where innovation, speed, and efficiency are crucial. The company creates massive wafer-scale engines, which are essentially dinner-plate-sized chips that integrate compute and memory to reduce latency. This specialized hardware supports both AI training and inference, offering these capabilities through physical data centers and flexible cloud services to customers worldwide. Its mission is to accelerate the development of artificial intelligence by providing a faster, more efficient alternative to standard industry processors.
On a trailing-12-month (TTM) basis through the June quarter, revenue reached nearly $681 million, representing a substantial 91% increase over the previous year. The company reported a net loss of $512 million during the same period.
Based on its June 2026 balance sheet, the current ratio is 5.8x, indicating the company’s ability to cover short-term debts with short-term assets. It carries a debt-to-equity ratio of 0.2x, indicating a small amount of debt relative to shareholders’ equity.
TTM free cash flow, which is cash from operations minus capital expenditures, was negative $680 million. This negative cash flow indicates the company is spending more on capital investments than it is generating from its core operations.
The case for Innodata
Innodata specializes in data engineering and evaluation frameworks that help major technology firms build generative AI systems. The company operates under master service agreements and counts five of the “Magnificent Seven” firms as major clients. Customer concentration like this adds a layer of risk to the business, as one specific customer accounted for nearly 58% of total revenue in 2025. Its strategy focuses on providing the human expertise and data labeling necessary to refine complex AI models.
TTM revenue reached $317 million as of the June quarter, representing a year-over-year increase of 39%. The company reported net income of roughly $47 million for the period, maintaining positive earnings for two consecutive years. Innodata has remained profitable over the last two fiscal years.
As for financial health, the June 2026 balance sheet shows a current ratio of nearly 1.7x, indicating strong short-term liquidity. The debt-to-equity ratio, which measures total debt relative to shareholders’ equity, is nearly 0.1x.
TTM free cash flow was approximately $184 million, providing cash for potential reinvestment.
Risk profile comparison
Cerebras Systems faces intense competition in the specialized hardware market, particularly from much larger incumbents with vast research budgets. The company must continually innovate to prove its wafer-scale architecture remains superior to more conventional networking and processing solutions.
Innodata contends with massive customer concentration, making it vulnerable to the budget shifts of just one or two major technology partners. Both Cerebras and Innodata face the same risk in terms of a broad slowdown in AI spending. Any slowdown in global AI infrastructure spending could impact their growth trajectory.
Valuation comparison
Innodata looks cheaper based on its P/S ratiomeasuring sales over the past twelve months, and its Forward P/E relative to future earnings estimates.
| Metric | Cerebras Systems | Innodata |
|---|---|---|
| Forward P/E | n/a | 35.5x |
| P/S ratio | 36.3x | 4.7x |
Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.
Which stock would I buy for 2027?
I would buy Innodata mainly because it is generating robust revenue growth and free cash flow, while Cerebras is reporting large losses on the bottom line. Analysts expect Innodata’s earnings to grow at an annualized rate of 22% in the coming years. That can support its forward P/E.
Innodata’s revenue surged 58% year over year in the second quarter, with adjusted operating profit up 92%. It is positioning itself as an AI deployment assurance layer to help enterprises safely use agents. It recently launched an AI Cyber Training Suite to train coding agents and fix issues in a company’s software.
I would wait to buy Cerebras until it shows a clearer path to sustainable cash flow growth. It has significant growth potential, with highly efficient, fast computing systems that could compete with traditional GPU-powered systems. Still, the stock is very expensive for a business that has not yet generated consistent profits.